ClinicaliQ Trial Snapshot
- An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma — Active Not Recruiting • Phase II • NCT02213926.
- Acalabrutinib showed safety and effectiveness in treating patients with relapsed or refractory mantle cell lymphoma.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL). Conditions: Mantle Cell Lymphoma (MCL) Interventions: ACP-196 (acalabrutinib) Lead Sponsor: Acerta Pharma BV Planned Enrollment: 124 participants